Anti-obesity drugs rose in popularity last year, helping the leaders in this market -- notably Eli Lilly and Novo Nordisk -- crush the market. However, some medical device specialists got the wrong end of the stick. That was the case with Abbott Laboratories (ABT -0.02%), whose diabetes care segment is perceived as its most important growth driver. Some investors thought GLP-1 medicines such as Ozempic could decrease demand for some of Abbott's key products. But that's not the case. Anti-obesity medicines w ...